View Scientific Rationale for Novel Therapeutics in Lung Cancer, And the Results of Clinical Trials to Date Inside 'Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents'
Posted on: Tuesday, 14 November 2006, 09:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c45155) has announced the addition of Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents to their offering.
In this triple analysis report we have analyzed three major and intertwined areas of cancer R&D, Non Small Cell Lung Cancer Therapeutics, Protein Kinase Inhibitors and Anti-angiogenesis and Vascular Targeting in Oncology, which are all subjects to an extensive number of innovative drug candidates. This extensive 280+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in the three mentioned key oncology areas. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.
Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced NSCLC. However, despite their contributions, science has reached a therapeutic plateau. Both Avastin and Efaproxyn have generated exciting data. In this report we are not only describing the progress of different combinations of approved drugs but as well the progress of 21 late stage drug candidates are described and analysed.
NSCLC Highlights:
Explore the strengths and weaknesses associated with compounds in clinical development.
Scientific rationale for novel therapeutics in lung cancer, and the results of clinical trials to date.
Gain insight into the current challenges and commercial opportunities associated with lung cancer
The number of protein kinase inhibitor (PKI) drugs has risen sharply, as the number of targets. The fiercest competition in PKI drug development is found in breast, lung, leukemia, prostate, and colorectal cancer. Several big pharma companies are out hunting for promising technology and drugs to complement their internal pipeline.
Protein Kinase Inhibitors in Oncology Highlights:
Drugs according to protein kinase target; Dual or multiple kinase inhibitor analysis
Targets according to indication
Competitive landscape assessment
Protein kinase inhibitors on market
Thorough review of the seven largest cancer indications in the field of protein kinase inhibitors
With Avastin as its bright star, the therapeutic field of anti-angiogenic and vascular targeting drugs in oncology is becoming re-energized. While fragmentation of the oncology market is set to occur as treatment becomes based on tumor growth drivers rather than primary tumor site, the use of targeted therapies, such as anti-angiogenesis, will occur in combination with traditional cytotoxic chemotherapy agents.
Anti-angiogenesis and Vascular Targeting Agents in Oncology Highlights
In-depth competitive landscape assessment of the anti-angiogenesis market in oncology
Thorough review of utilized targets in anti-angiogenic and vascular target drug development
Thorough review of approved drugs
Progress analysis of five major cancer indications, including players, drugs, clinical progress and pitfalls
Content Outline:
1 Executive Summary
2 Table of Contents
3 Methodology
4 Protein Kinase Inhibitors
5 Anti-Angiogenesis & Vascular Targeting
6 Non Small Cell Lung Cancer
7 Progress in Current Treatment Strategies
8 Key Drug Strategies in Lung Cancer
9 Competitive Landscape in Non Small Cell Lung Cancer Drug Development:
The Late Stage Pipeline
10 Disclaimer
11 Appendix I: Complete List of Angiogenic and Vascular Target Agents in
Development in Oncology
12 Appendix II: Treatment Guide Lines
14 Company Index
15 Drug Index
2.1 List of Boxes
2.2 List of Figures
2.3 List of Tables
Companies & Products Mentioned
Novartis
AstraZeneca
Pfizer
GlaxoSmithKline
Docetaxel
Vinorelbine
Gemcitabine
Paclitaxel
Pemetrexed
Gefitinib
Erlotinib
For more information visit http://www.researchandmarkets.com/reports/c45155
Source: Business Wire
Related Articles
- Oncothyreon Files New Drug Application for Oncology Drug
- Gain Competitive Insight into 123 Anti-Angiogenic Drugs, Under Development By 90 Investigators
- Dr. Thomas Okarma Resumes Direct Leadership of Geron's Oncology Drug Development Activities
- Oncologic Drugs Advisory Committee Recommends FDA Wait for Overall Survival Analysis of Satraplatin for Treatment of Hormone-Refractory Prostate Cancer
- Safety of Anti-Anemia Drugs for Chemotherapy Patients Questioned; This Week on Your Cancer Today(TM)
- Abraxis Provides Update on Oncologic Drugs Advisory Committee Recommendation Regarding ABRAXANE Trial Design for Adjuvant Therapy for Node-Positive Breast Cancer
- Kemia Announces Completion of Phase I Trials for Oral Anti-Inflammatory Drug; KC706, a P38 MAP Kinase Inhibitor, Targets Inflammatory Conditions Including Arthritis, Psoriasis, and Cardiovascular Disease
- Cytotoxic Treatments Play a Critical Role in Modern Cancer Therapy - Target-Based Approaches for Discovering Novel Oncology Drugs
- Spectrum Pharmaceuticals to Acquire NDA for an Oncology Drug and Other Assets
- Take a Look at the Target-Based Approaches for Discovering Novel Oncology Drugs
User Comments (0)
RSS Feeds